The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Download
Associated Records
File Licence
Editors
Date
2015-02-03
Source Title
F1000prime reports
Journal Title
Journal ISSN
Volume Title
Publisher
Faculty Opinions Ltd
Melbourne Authors
Affiliation
Biochemistry and Molecular Biology
Document Type
Journal Article
Subject Code
Citation
Brown, K. K. & Toker, A. (2015). The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000prime Reports, 7, pp.13-. https://doi.org/10.12703/P7-13.
Access Status
Open Access
DOI
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.